PMID- 26155406
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 4
IP  - 5
DP  - 2015 May
TI  - Deciphering the genetic evolution of T-cell resistance in melanoma.
PG  - e1005510
LID - e1005510
AB  - T-cell-based immunotherapy of melanoma becomes ineffective when beta2m-deficient 
      tumor cells of a human leukocyte antigen (HLA) class I-negative phenotype grow 
      out. We demonstrated that an early-acquired chromosomal deletion and subsequent 
      inactivating gene mutation lead to beta2m deficiency, suggesting that melanoma cells 
      can genetically evolve to avoid being recognized by CD8(+) T cells.
FAU - Sucker, Antje
AU  - Sucker A
AD  - Department of Dermatology; University Hospital; University Duisburg-Essen and 
      German Cancer Consortium (DKTK) ; Essen, Germany.
FAU - Paschen, Annette
AU  - Paschen A
AD  - Department of Dermatology; University Hospital; University Duisburg-Essen and 
      German Cancer Consortium (DKTK) ; Essen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20150203
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC4485751
OTO - NOTNLM
OT  - CD8+ T cells
OT  - HLA class I loss
OT  - genetic alterations
OT  - melanoma
OT  - beta2m deficiency
EDAT- 2015/07/15 06:00
MHDA- 2015/07/15 06:01
PMCR- 2016/02/03
CRDT- 2015/07/09 06:00
PHST- 2014/12/30 00:00 [received]
PHST- 2015/01/01 00:00 [accepted]
PHST- 2015/07/09 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/07/15 06:01 [medline]
PHST- 2016/02/03 00:00 [pmc-release]
AID - 1005510 [pii]
AID - 10.1080/2162402X.2015.1005510 [doi]
PST - epublish
SO  - Oncoimmunology. 2015 Feb 3;4(5):e1005510. doi: 10.1080/2162402X.2015.1005510. 
      eCollection 2015 May.